ID   H69AR
AC   CVCL_3513
SY   H-69AR; NCI-H69AR
DR   BTO; BTO:0005367
DR   CLO; CLO_0003610
DR   ArrayExpress; E-MTAB-38
DR   ATCC; CRL-11351
DR   GEO; GSM169453
DR   GEO; GSM170728
DR   GEO; GSM827497
DR   GEO; GSM986176
DR   IGRhCellID; H69AR
DR   Progenetix; CVCL_3513
DR   Wikidata; Q54872205
RX   Patent=US5489519;
RX   PubMed=1314068;
RX   PubMed=2436751;
RX   PubMed=17426248;
RX   PubMed=20215515;
RX   PubMed=28196595;
CC   Group: Patented cell line.
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11351.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 11
ST   D5S818: 11,13
ST   D7S820: 9
ST   TH01: 8,9
ST   TPOX: 10
ST   vWA: 16,17
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1579 ! NCI-H69
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 25
RX   Patent=US5489519;
RA   Deeley R.G., Cole S.P.C.;
RT   "Multidrug resistance protein.";
RL   Patent number US5489519, 06-Feb-1996.
RX   PubMed=1314068; DOI=10.1038/bjc.1992.103;
RA   Cole S.P.C., Pinkoski M.J., Bhardwaj G., Deeley R.G.;
RT   "Elevated expression of annexin II (lipocortin II, p36) in a multidrug
RT   resistant small cell lung cancer cell line.";
RL   Br. J. Cancer 65:498-502(1992).
RX   PubMed=2436751;
RA   Mirski S.E.L., Gerlach J.H., Cole S.P.C.;
RT   "Multidrug resistance in a human small cell lung cancer cell line
RT   selected in adriamycin.";
RL   Cancer Res. 47:2594-2598(1987).
RX   PubMed=17426248; DOI=10.1158/1541-7786.MCR-06-0367;
RA   Olejniczak E.T., Van Sant C., Anderson M.G., Wang G., Tahir S.K.,
RA   Sauter G., Lesniewski R., Semizarov D.;
RT   "Integrative genomic analysis of small-cell lung carcinoma reveals
RT   correlates of sensitivity to bcl-2 antagonists and uncovers novel
RT   chromosomal gains.";
RL   Mol. Cancer Res. 5:331-339(2007).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).